CPI Pharmacology & Medication Management 3 — Questions and Answers
Question 1: A blinded Phase III trial uses placebo control. The study drug is a capsule with a distinctive bitter taste. Participants frequently guess their assignment. This is an example of which methodological problem?
- Unblinding due to pharmacological clues (Correct answer)
- Selection bias in randomization
- Attrition bias from dropouts
- Detection bias in outcome ascertainment
Correct answer: Unblinding due to pharmacological clues
Distinctive organoleptic properties such as taste or smell can unblind participants, compromising the integrity of blinding and introducing performance and reporting bias.
Question 2: A participant on warfarin enrolls in a trial of an azole antifungal. The azole inhibits CYP2C9. What is the expected pharmacodynamic consequence?
- Increased anticoagulant effect and bleeding risk (Correct answer)
- Decreased anticoagulant effect and clotting risk
- No change in INR
- Enhanced warfarin protein binding
Correct answer: Increased anticoagulant effect and bleeding risk
CYP2C9 metabolizes the more potent S-warfarin; CYP2C9 inhibition raises warfarin levels, intensifying anticoagulation and increasing hemorrhage risk.
Question 3: An investigator is designing a First-in-Human (FIH) trial. The starting dose is calculated using the NOAEL from animal studies. The human equivalent dose (HED) is derived by:
- Dividing the animal NOAEL by an allometric scaling factor based on body surface area (Correct answer)
- Multiplying the animal NOAEL by the animal's body weight in kg
- Using the animal NOAEL directly without adjustment
- Applying a fixed 10-fold safety factor to the animal ED50
Correct answer: Dividing the animal NOAEL by an allometric scaling factor based on body surface area
HED is calculated by dividing the animal NOAEL (in mg/kg) by a body surface area conversion factor (Km ratio), then applying a safety factor to determine the maximum recommended starting dose.
Question 4: In a trial, drug X has a narrow therapeutic index and is 95% protein-bound. A co-administered drug Y displaces X from albumin binding sites. What is the immediate pharmacokinetic effect?
- Transient increase in free (unbound) drug X, rapidly corrected by increased clearance (Correct answer)
- Sustained doubling of free drug X causing chronic toxicity
- Decreased total drug X concentration in plasma
- No clinically significant effect
Correct answer: Transient increase in free (unbound) drug X, rapidly corrected by increased clearance
Protein displacement briefly raises free drug levels, but the increased free fraction also increases clearance and distribution, usually returning unbound concentrations to near-baseline rapidly.
Question 5: A participant in an oncology trial develops grade 3 thrombocytopenia (platelets 25,000/µL). Per ICH E6 GCP guidelines, what is the investigator's primary obligation regarding this event?
- Assess causality, treat the participant, and report as a serious adverse event to the sponsor (Correct answer)
- Discontinue all study medications immediately without assessment
- Report only to the IRB and not the sponsor
- Continue the study drug with dose reduction and observe
Correct answer: Assess causality, treat the participant, and report as a serious adverse event to the sponsor
Grade 3 thrombocytopenia is serious; the investigator must ensure participant safety, assess causality, and report the SAE to the sponsor within required timeframes per ICH E6.
Question 6: A study evaluates an inhaled bronchodilator. Pharmacodynamic endpoints include FEV1 improvement. Which PK/PD model best describes the relationship between bronchodilator plasma concentration and FEV1 response?
- Sigmoidal Emax (Hill) model (Correct answer)
- Linear PK/PD model
- Effect compartment turnover model
- Biophase equilibration model with direct link
Correct answer: Sigmoidal Emax (Hill) model
The sigmoidal Emax model describes pharmacological responses that plateau at maximum effect (Emax) with a sigmoidal concentration-response curve characterized by EC50 and the Hill coefficient.
Question 7: A trial sponsor changes the reference safety information (RSI) to remove a previously listed adverse event. How does this affect reporting obligations for that event going forward?
- Events previously labeled as expected now become unexpected, triggering expedited SUSAR reporting (Correct answer)
- Reporting obligations are unaffected as historical labeling is used
- The event no longer needs to be reported
- The event must be downgraded from SAE to non-serious
Correct answer: Events previously labeled as expected now become unexpected, triggering expedited SUSAR reporting
The current RSI at the time of the event determines whether an adverse reaction is expected or unexpected; removing an event from the RSI reclassifies it as unexpected, requiring SUSAR reporting.
CPI Pharmacology & Medication Management 3
A blinded Phase III trial uses placebo control.
The study drug is a capsule with a distinctive bitter taste.
Participants frequently guess their assignment.
This is an example of which methodological problem?